{"name":"Virometix","slug":"virometix","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxQemJjNlpoMng3VXNVczhBQVEyOUhZbGdtMU9QellJSkJZVlVVc3d6NHZkWDV2T2VvVEpIeEUzUTh3b29jbzlqdkV3UjV2U29EYm1SWnlfc21EOUw0Uk5nVWg4Vk1RdC1fd3pqU0g5ck5EdmQ1MjZ4WkEybzFLTjlxLUlvMVlxZWxnT1BQVzRhaEdOZm9BcUNMNFNINlZFTGpsX1RGRWtOQ1cxNUN1Vi1WRTNTd1RrQVM2YWRYTUthZnFLLTYzWlpRQl9QLS0xWmZ4ckpYZ3g1UUJRakZReEdWZWM1WWVQNm5vU0U5Xy1RdkRTOXRWM3VWRTVLUXRXckxPT3ZDNTNZRmE0dGhOcWJlWW1XOFdUVEdWc0x5aDlEZXdOLXlyNDhEWk9ZNlNVTXpCb2IwMUNFejBjbzJOVVl6cXM3bEUzN1FXNzNaZGxDaXVKVzA?oc=5","date":"2026-01-08","type":"trial","source":"Business Wire","summary":"Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease - Business Wire","headline":"Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Develo","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxNaXdtUlY1VjNfcWNnNHlrUGoyeXhqUmN6R3dmMlJ0U2N3bzNTSkZCaXk5UnpQaVNPck9LeHJxSEx4Z280S2xsYmdOdjQxS3h1bnBsOEotNHB0Tmo2UHNlNnV6WXZnZVdwcndtekFCQVhJYm5xeDVEdDV6LWtWUlEzd3l5UVNCTnNBY1lpaHBjbHN6QmJHMDVSWTgtdXowYlZsMnNqaG04MW5uTFFRUmU1WHVUbmI5bnltanBLblZSRkpxUDlGTWV0dXBiUTVOLVkzZ0xQRnY0VjBPaHNTNHlDb1I2RzhoZGlVSm0wUW9XU1JjUWNvZmpaTGRmdm5xUF9EcXVIdmxXZk1PQkkxR0NRRlJDVEp2c0prWjdsc3FzOA?oc=5","date":"2025-11-13","type":"pipeline","source":"Business Wire","summary":"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines - Business Wire","headline":"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Syn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxNVHUzdEtfbExhSWNxaDhLTGhtamR1X3dhNFo3d1p4emw2VnRXTmlOVThwN09zam1sRFg0SXhxSlBOdmFqYzhPb2pid2ZZdE0tSTF5VkpTR0tINjM1eHdMTWZCSDFad0cwS1NQNmVmdGZlRGFTNHZYajRzZEdoX0VLaG1CTTBlVW5iQ3BIVXRfTUlPM1l0QjY1bGhwbU9TU2liZkZLbXh4Z0NkU1lZbFFfSlMzSk1KUnNKWmRtVXFIZ3EwX2UtM0M5QXk2ZWxIZVQ3SGdJZlMwM01rODUxaG5YbzZtSzRYT1N3Mk5qLUcyaGQ2azJPdTRyRHJBaGF5Y3AwTVA5TW0zbFJfVkw5Q0x1R1Q3aVNNcWlabUo5R1YxMnRWUnJMTXhmbVhQam1sT3BaM0IwcDFfdHQwN1F2RkE?oc=5","date":"2025-09-29","type":"trial","source":"Business Wire","summary":"Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae - Business Wire","headline":"Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE44U09IODFNLWFZX1ktejZuMElGU0ZzVWJuMjJ1R2wyVkVHdWduaVF2VXY2Ulc5WFZQN3JPZWxqOUVTa0dSa0JXb190enZhelMyT2ZqbVVXTVFhTmV1dTFvbTZLRFA1VUNSc0ZPbHlRYklROFlidEdUdnhQZHdqUQ?oc=5","date":"2019-02-04","type":"pipeline","source":"Startupticker.ch","summary":"Anna Sumeray takes the lead at Virometix - Startupticker.ch","headline":"Anna Sumeray takes the lead at Virometix","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}